Kewaunee Scientific (KEQU) AI Stock Analysis

• Market Cap: $99.46M
• Dividend Yield: N/A
• Average Volume (3M): 8.77K
• Price to Earnings (P/E): 40.9
• Beta (1Y): 0.75
• Revenue Growth: 43.02%
• EPS Growth: -37.24%
• Country: US
• Employees: 1,006
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Furnishings, Fixtures & Appliances
• EPS (TTM): 0.23
• Shares Outstanding: 2,866,384
• 10 Day Avg. Volume: 10,539
• 30 Day Avg. Volume: 8,774
• PEG Ratio: -0.20
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.38
• P/FCF Ratio: 7.18
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 0.52
• Enterprise Value/Gross Profit: 1.78
• Enterprise Value/Ebitda: 5.56
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $37.00 ▼(-3.52% Downside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is driven primarily by improved financial performance (profitability rebound, strong revenue growth, and solid positive free cash flow), tempered by increased leverage. Technicals are weak with the stock below major moving averages and negative momentum, while valuation is elevated on a high P/E with no dividend support. Corporate events are modestly positive but hinge on forthcoming results.

Positive Factors

Revenue growth & profitability rebound

Sustained ~78% TTM revenue growth and return to profitability reflect durable demand for lab build-outs and strong project execution. Over 2–6 months this expands operating leverage, supports reinvestment in production and sales, and strengthens the firm's ability to fund growth without relying solely on external capital.

Strong cash generation

Consistent positive OCF and FCF provide durable internal funding for capex, working capital and potential debt paydown. With FCF roughly 84% of net income, the company has improved financial flexibility to support project delivery and withstand intermediate cyclical headwinds in lab construction markets.

Broader product ecosystem from Nu Aire

The Nu Aire acquisition expands Kewaunee's specified product set, enabling more integrated lab solutions. Structurally this can raise win rates on large projects, improve cross-sell, and deepen customer stickiness across research, healthcare and education segments, supporting sustainable revenue mix diversification.

Negative Factors

Rising leverage

Higher debt levels reduce financial flexibility and elevate refinancing and interest-rate risk if project volumes slow. For a project-driven business, increased leverage constrains the firm's ability to bid aggressively, invest in capacity, or absorb delays in receivables without eroding liquidity.

Modest net margin and profit sensitivity

A modest TTM net margin (~3.9%) and variability versus prior periods indicate underlying earnings are sensitive to input costs, project mix and non-operating items. This reduces predictability of retained earnings and makes cash conversion and debt repayment more contingent on stable margins.

Limited cash coverage of debt

Although cash generation is positive, OCF covering under half of total debt signals moderate coverage. That level limits the firm's ability to rapidly deleverage or absorb cyclical downturns without tapping reserves or new financing, raising medium-term solvency risk if revenues soften.

Kewaunee Scientific Business Overview & Revenue Model

Company Description

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates through two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, its subidiaries, and a national distributor. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.

How the Company Makes Money

Kewaunee Scientific makes money primarily by selling and delivering laboratory furniture and integrated lab environments to institutional and commercial customers. Its core revenue stream is product sales (e.g., laboratory casework, benches/workstations, fume hoods, and related lab fixtures/components) that are typically specified into lab construction or renovation projects and then manufactured and delivered to the job site. A significant portion of revenue is also tied to project execution services associated with those product orders—such as design/engineering support, project management, installation, and commissioning—where the company earns revenue as projects progress and are completed under customer contracts. Earnings are influenced by the volume and mix of laboratory build-outs and renovations (often tied to capital spending by universities, government, healthcare, and private industry), competitive bidding/specification win rates, manufacturing utilization, and input costs (materials, labor, and freight). Specific material partnerships, customer concentration details, or quantified revenue breakdowns by stream are null.

Kewaunee Scientific Financial Statement Overview

Summary

Improving fundamentals with strong TTM revenue growth (~78%) and a clear rebound to profitability, supported by positive operating cash flow (~$22.6M) and free cash flow (~$19.1M). Offsetting factors include modest TTM net margin (~3.9%) vs. prior strength and rising leverage (debt/equity ~0.84) with only moderate cash-flow coverage of total debt.

Income Statement

KEQU shows a strong profitability rebound versus the loss-making period in 2021–2022, with solid operating profitability in the most recent periods. TTM (Trailing-Twelve-Months) revenue growth is very strong (about 78%), and operating margins are healthy (EBIT margin ~7.1%, EBITDA margin ~9.3%). Offsetting this, net margin in TTM (Trailing-Twelve-Months) is modest (~3.9%) and down from the unusually strong 2024 level, indicating profits can be somewhat volatile and sensitive to costs/mix.

Balance Sheet

The balance sheet is adequate but shows rising leverage. Debt relative to equity increased from a low level in 2024 to ~0.84 in TTM (Trailing-Twelve-Months), and total debt is materially higher than prior years, which adds financial risk if demand softens. A key positive is that shareholder returns remain solid (return on equity ~16% in TTM (Trailing-Twelve-Months)), suggesting the company is generating decent earnings on its capital base despite the higher leverage.

Cash Flow

Cash generation is a notable strength recently: TTM (Trailing-Twelve-Months) operating cash flow (~$22.6M) and free cash flow (~$19.1M) are firmly positive, a sharp improvement from negative cash flow in 2022–2023. Free cash flow is reasonably well-supported by earnings (free cash flow is ~84% of net income). The main watch-out is that cash flow coverage of debt remains moderate (operating cash flow covers less than half of total debt in TTM (Trailing-Twelve-Months)), and free cash flow growth has been uneven year-to-year.

Breakdown	TTM	Apr 2025	Apr 2024	Apr 2023	Apr 2022	Apr 2021
Income Statement
Total Revenue	287.75M	240.47M	203.75M	219.49M	168.87M	147.47M
Gross Profit	83.23M	68.86M	52.05M	35.59M	24.22M	23.99M
EBITDA	26.69M	22.76M	18.04M	8.16M	916.00K	459.00K
Net Income	11.08M	11.40M	18.75M	1.36M	-6.00M	-3.61M
Balance Sheet
Total Assets	175.96M	194.65M	134.77M	118.90M	118.77M	89.38M
Cash, Cash Equivalents and Short-Term Investments	10.35M	14.94M	23.27M	8.08M	4.43M	5.21M
Total Debt	59.34M	50.16M	11.00M	12.92M	67.56M	16.15M
Total Liabilities	103.43M	128.41M	78.56M	80.41M	82.59M	47.90M
Stockholders Equity	70.67M	64.46M	54.76M	37.41M	35.69M	41.24M
Cash Flow
Free Cash Flow	19.05M	12.62M	15.19M	-7.94M	-9.79M	-1.49M
Operating Cash Flow	22.58M	14.78M	19.56M	-3.79M	-7.88M	912.00K
Investing Cash Flow	-3.52M	-30.90M	-4.37M	-4.15M	-1.91M	-2.40M
Financing Cash Flow	-20.71M	7.41M	-3.01M	14.93M	11.03M	1.98M

Kewaunee Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Negative. The current price of 38.35 is below the 20-day moving average (MA) of 40.56, below the 50-day MA of 39.62, and below the 200-day MA of 44.65, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 28.99 is Positive, neither overbought nor oversold. The STOCH value of 5.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KEQU.

Kewaunee Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLXS	71 Outperform	$242.74M	7.91	12.37%	1.77%	6.00%	64.58%
ETD	70 Outperform	$564.65M	12.45	9.20%	7.86%	-4.26%	―
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
KEQU	61 Neutral	$99.46M	40.94	16.29%	―	43.02%	-37.24%
BSET	57 Neutral	$124.36M	22.07	3.67%	4.59%	-2.74%	―
HOFT	54 Neutral	$138.17M	-1.14	-15.57%	7.20%	-12.09%	-204.66%
VIRC	47 Neutral	$98.82M	-21.77	3.48%	1.59%	-27.97%	-83.58%

Kewaunee Scientific Corporate Events

Kewaunee Scientific Sets Date for Q3 2026 Results

On February 25, 2026, Kewaunee Scientific Corporation announced it will release its third quarter fiscal 2026 financial results after the market close on March 11, 2026, with the information to be made available on its website. The timing of this announcement signals an upcoming update on the company’s operating performance, which will be closely watched by investors following its recent expansion into complementary laboratory equipment through the Nu Aire acquisition.

Kewaunee Scientific, a long-established supplier of laboratory and technical furniture with a growing global footprint, is positioning itself as a more integrated provider of lab infrastructure solutions. The addition of Nu Aire’s biological safety cabinets, CO2 incubators, and ultralow freezers broadens the company’s product ecosystem, potentially enhancing its competitive standing in both domestic and international laboratory markets ahead of the forthcoming earnings release.

The most recent analyst rating on (KEQU) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.